These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35076567)

  • 21. Primary central nervous system lymphoma.
    Gerstner ER; Batchelor TT
    Arch Neurol; 2010 Mar; 67(3):291-7. PubMed ID: 20212226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
    Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
    Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry.
    Krogh-Jensen M; D'Amore F; Jensen MK; Christensen BE; Thorling K; Pedersen M; Johansen P; Boesen AM; Andersen E
    Leuk Lymphoma; 1995 Oct; 19(3-4):223-33. PubMed ID: 8535213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates of primary central nervous system lymphoma.
    Wu J; Zhou D; Zhu X; Zhang Y; Xiao Y
    Ther Adv Hematol; 2024; 15():20406207241259010. PubMed ID: 38883164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.
    Zhai Y; Zhou X; Wang X
    Ther Adv Med Oncol; 2022; 14():17588359221093745. PubMed ID: 35558005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary central nervous system lymphoma.
    Batchelor TT
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):379-385. PubMed ID: 27913504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biology and treatment of primary central nervous system lymphoma.
    Algazi AP; Kadoch C; Rubenstein JL
    Neurotherapeutics; 2009 Jul; 6(3):587-97. PubMed ID: 19560747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary central nervous system lymphoma: essential points in diagnosis and management.
    Paydas S
    Med Oncol; 2017 Apr; 34(4):61. PubMed ID: 28315229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
    Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
    Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
    Steffanoni S; Batchelor TT
    Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
    Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
    J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
    Grommes C; Younes A
    Cancer Cell; 2017 Jun; 31(6):731-733. PubMed ID: 28552326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report.
    Mair A; Muigg A; Stockhammer G; Mangesius S; Wolf D; Gunsilius E
    Case Rep Oncol; 2021; 14(3):1337-1341. PubMed ID: 34720938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central Nervous System Lymphomas.
    Grommes C
    Continuum (Minneap Minn); 2020 Dec; 26(6):1476-1494. PubMed ID: 33273169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
    Lionakis MS; Dunleavy K; Roschewski M; Widemann BC; Butman JA; Schmitz R; Yang Y; Cole DE; Melani C; Higham CS; Desai JV; Ceribelli M; Chen L; Thomas CJ; Little RF; Gea-Banacloche J; Bhaumik S; Stetler-Stevenson M; Pittaluga S; Jaffe ES; Heiss J; Lucas N; Steinberg SM; Staudt LM; Wilson WH
    Cancer Cell; 2017 Jun; 31(6):833-843.e5. PubMed ID: 28552327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the therapy of primary central nervous system lymphoma.
    Plotkin SR; Batchelor TT
    Clin Lymphoma; 2001 Mar; 1(4):263-75; discussion 276-7. PubMed ID: 11707839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introduction of novel agents in the treatment of primary CNS lymphoma.
    Grommes C; Nayak L; Tun HW; Batchelor TT
    Neuro Oncol; 2019 Feb; 21(3):306-313. PubMed ID: 30423172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
    Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
    Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.